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Abstract.  SPARC is a transiently expressed extracellu- 
lar matrix-binding  protein that alters cell shape and 
regulates endothelial cell proliferation in vitro. In this 
study, we show that SPARC mRNA and protein are 
synthesized by endothelial cells during angiogenesis in 
vivo. SPARC and peptides derived from a cationic re- 
gion of the protein (amino acids 113-130) stimulated 
the formation of endothelial cords in vitro; moreover, 
these peptides stimulated angiogenesis in vivo. Map- 
ping of the active domain demonstrated that the se- 
quence KGHK was responsible for most of the angio- 
genie activity; substitution of the His residue 
decreased the effect. We found that proteolysis of 
SPARC provided a  source of KGHK, GHK, and 
longer peptides that contained these sequences. A1- 
though the Cu2+-GHK complex had been identified as 
a mitogen/morphogen in normal human plasma,  we 
found KGHK and longer poptides to be potent stimu- 
lators of angiogenesis.  SPARCm.t30 and KGI-IK were 
shown to bind Cu  2+ with high affinity; however, previ- 
ous incubation with Cu  2+ was not required for the 
stimulatory activity. Since a peptide from a second 
cationic region of SPARC (SPARC~73) also bound 
Cu  2+ but had no effect on angiogenesis, the angiogenic 
activity appeared to be sequence specific/and indepen- 
dent of bound Cu  2+. Thus,  specific degratlation of 
SPARC,  a matrix-associated protein expressed by en- 
dothelial cells during vascular remodeling,  releases a 
bioactive peptide or peptides, containing the sequence 
(K)GHK, that could regulate angiogenesis in vivo. 
T 
HE extracellular  matrix is a repository for a number 
of growth-regulatory factors (Flaumenhaft  and Rif- 
kin,  1992).  In addition,  matrix proteins themselves 
clearly influence  the proliferative  and migratory status of 
cells (Ingber and Folkman,  1989a,  1989b).  The promotion 
of growth in vitro by extracellular  matrix components has 
generally been attributed to shape changes that result from 
interactions  between cells and their substrates  (Folkman and 
Moscona, 1978; Form et al., 1986; Ingber,  1990; DAmore, 
1992).  However,  several  matrix-associated  proteins  also 
manifest growth stimulatory activity that is independent of 
their adhesive properties.  For example,  peptides from an 
EGF-like domain of laminin  have been shown to stimulate 
cell replication  in vitro (Panayotou  et al.,  1989).  Because 
such proteins are immobilized on cell surfaces and in the ex- 
tracellular matrix, they might provide a localized source of 
growth-regulatory  activity (Engel,  1989);  moreover,  they 
could be a source of diffusible morphogens through proteo- 
lytic processing and turnover.  Recently, cationic  sequences 
within  a  follistatin-like  domain of SPARC (see Lane and 
Sage, 1994) have been shown to regulate the proliferation  of 
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endothelial  cells in vitro (Funk and Sage, 1991, 1993). Cat- 
ionic region 1 (amino acids 54-73) was shown to inhibit the 
proliferation  of subconfluent endothelial  cells, whereas cat- 
ionic region 2 (amino acids 113-130) stimulated  DNA syn- 
thesis,  an activity that is masked in the intact protein. 
SPARC is a highly conserved, matrix-associated  glycopro- 
tein transiently  expressed during the embryonic development 
of vertebrates (Mason et al.,  1986a,  1986b; Holland et al., 
1987; Damjanovski  et al.,  1992).  It is a major secretory 
product  of embryonic parietal  endoderm  (Mason  et  al., 
1986a),  osteohlasts  (Otsuka  et al.,  1984;  Whitson et al., 
1984),  odontoblasts (Fujisawa  and Kubold,  1989;  Sage et 
al., 1992), and fibrohlasts OVasi et al., 1984). In adults, ex- 
pression is limited but has been identified in tumors (Dzia- 
dek et al.,  1986; Wewer et al.,  1988; Schuiz et al.,  1988) 
and in a variety of tissues undergoing cellular remodeling or 
renewal (Holland et al.,  1987; Sage et al., 1989a; Raines et 
al.,  1992; Reed et al.,  1993). Overexpression  of SPARC in 
vertebrates and invertebrates  results in extensive disruptions 
of the body axis that are consistent with a role in cellular at- 
tachment  and  morphogenesis  of structures  derived  from 
mesoderm  (Schwarzbauer  and  Spencer,  1993;  Lane  and 
Sage,  1994). 
SPARC is also expressed by cultured endothelial cells and 
is  increased  further  when these  cells  form  cords  and/or 
tubes, a  type of remodeling termed angiogenesis  in vitro 
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influences  endothelial  cell  shape,  protein  synthesis,  and 
proliferation (Sage and Bomstein,  1991). SPARC also binds 
several  divalent  cations  that include  copper  (Vernon  and 
Sage,  1989); both Cu  2+ and Cu2+-binding  proteins/peptides 
have been shown to stimulate angiogenesis in vivo (McAus- 
lan et al.,  1980; Raju et al,,  1982). These and other studies 
collectively  indicate that SPARC might be important in the 
regulation of endothelial function, although expression has 
not previously been demonstrated in endothelial cells under- 
going angiogenesis in vivo. 
In this study, we show that SPARC is transiently expressed 
in endothelial cells associated with angiogenesis in vivo. In 
an assay of angiogenesis in vitro, SPARC stimulated the for- 
marion of endothelial cords.  Mapping of the active domain 
with synthetic peptides derived from SPARC identified cat- 
ionic region 2 as a potent source of angiogenic activity. Al- 
though SPARC itself appeared to be a marginal stimulator 
of angiogenesis in vivo, peptides derived from cationic re- 
gion 2 were active stimulators of capillary growth in vivo and 
in vitro. The active peptides corresponded to a novel Cu  2+- 
binding  domain  in  SPARC  and  overlapped  the  sequence 
GHK at amino acid 120 of the secreted sequence. N-glycyl- 
l:histidyl-L-lysine-OH  (GHK) 1 (also  referred  to  as  liver 
growth factor) is a Cu2+-binding  peptide, isolated originally 
from human plasma, which has been shown to induce angio- 
genesis in the chicken chorioallantoic membrane (CAM) and 
to  accelerate  the  closure  of dermal  wounds  (Raju et al., 
1982;  Pickart,  1983;  Pickart  and  Lovejoy,  1987).  The 
identification of sequences related to GHK as sources of.an- 
giogenic  activity in SPARC prompted us to investigate the 
relationship between Cu  2+-binding  and angiogenic activity, 
as well as the possibility that SPARC is a source of GHK- 
containing peptides in vivo.  We provide evidence that the 
binding of Cu  2+ is not sufficient to stimulate angiogenesis 
because  a  second  pepride  that bound  Cu  2+  was  inactive. 
Thus, stimulation of angiogenesis by Cu2+-binding  peptides 
from cationic region 2 appears to be sequence specific.  Fi- 
nally, SPARC was a substrate for several proteases that have 
been implicated in angiogenesis. Incubation with plasmin, as 
well as the serine protease trypsin,  resulted in cleavage at 
several sites and the release of peptides from cationic region 
2. SPARC could, therefore, be a source of GHK-containing 
peptides,  released  during the  degradation  of extracellular 
matrix, in remodeling tissues that exhibit high levels of an- 
giogenesis. 
Materials and Methods 
7Issue Preparation 
Female Swiss-Webster mice were mated and checked for insemination  plugs 
daily. The morning that followed successful  mating was considered to be 
day 1 after conception. Gestation was terminated between days 11 and 18, 
and embryos were fixed in either 3% paraformaldehyde/0.1  M NaPO4 (pH 
7.4) for analysis of RNA transcripts or in methyl-Carnoy's  solution (30% 
CCh,  10% CH3COOH,  60% CH3OH) for immunohistochemistry.  Fixed 
embryos, staged by morphological criteria (Rafferty, 1970), were embedded 
I. Abbreviations used in this paper: BAE, bovine aortic endothelial; bFGF, 
basic  fibroblast growth  factor;  CAM,  chorioallantoic membrane;  Cu- 
IMAC, copper-immobilized  metal affinity chromatography; GI-IK, N-gly- 
cyl-L-histidyl-L-lysine-OH;  KGHK,  N-lysyl-L-glycyl-L-histidyl-L-lysine- 
OH; PCNA, proliferating cell nuclear antigen. 
in paraffin, and 5-~,m sections were mounted on microscope slides (Probe- 
on"; Fisher Scientific,  Pittsburgh, PA). 
In Situ Hybridization and Immunohistochemistry 
Riboprobes consisted of 3sS-UTP-labeled  single-stranded transcripts de- 
rived from a full-length mouse SPARC cDNA (1,147 bp) inserted into the 
multiple cloning site of the plasmid pGEM-1  linearized with BamHI or 
HindlII (Mason et al.,  1986a).  Sense-strand riboprobes were produced in 
transcription  reactions initiated from the T7 promoter of plasmids made lin- 
ear with HindIH. Antisense riboprobes were produced in reactions initiated 
from the SP6 promoter of plasmids made linear with BamHI.  Riboprobes 
were hydrolyzed  to an average  length of 250 bp by alkaline hydrolysis, 
reprecipitated in ethanol, and resuspended in 10 mM dithiothreitol before 
use in hybridization experiments. In situ hybridization  was performed as de- 
scribed by Iruela-Arispe et al. (1993). Detection of SPARC transcripts re- 
quired 10-15-d  exposures.  Immunohistochemistry was performed as de- 
scribed (Reed  et al.,  1993)  with an aflinity-puKfied  rabbit antipeptide 
antiserum (SPARC 16-35; c~M1.2) that recognizes  intact SPARC. This IgG 
has been shown to precipitate SPARC from solution and is completely neu- 
tralized by absorption with the immunizing peptide.  Serial sections were 
also  reacted with biotinyiated B4 lectin from Bandeiraea  simplicifolia 
(BSLB4) (Vector Laboratories, Inc., Burlingame,  CA), or with a monoclo- 
hal  antibody  (IgG)  against proliferating cell  nuclear  antigen (PCNA) 
{Boehringer  Mannheim Corp.,  Indianapolis,  IN).  A  biotinylated goat 
anti-mouse IgG (Vector Laboratories, Inc.) was used as a secondary anti- 
body. Antibody and lectin complexes were detected with an avidin-biotin- 
horseradish peroxidase system or were visualized by fluorescence  micros- 
copy with avidin-FITC  or avidin-rhodamine as fluorochromes. 
Purification of  SPARC and Peptide Synthesis 
Murine SPARC was purified from PYS-2 cells as described by Sage et al. 
(1989a),  and human SPARC from platelets  was obtained from Haemato- 
logic Technologies,  Inc. (Essex Junction, VT). Peptide synthesis was car- 
ried out as described (Lane and Sage, 1990). Peptides were synthesized with 
N~-9-fluorenylmethyloxycarbonyl  (f-moc) amino acid derivatives by Dr. K. 
De Jongh and A. Colvin (Molecular Pharmacology Facility, University of 
Washington). The location and amino acid sequence of peptides used in this 
study are shown in Table I. Sequences were derived and numbered based 
on the predicted amino acid sequence of mature murine SPARC after 
removal of the signal sequence (Mason et al., 1986a). We also synthesized 
peptides  with amino acid substitutions (mutations), which are designated 
by single letter codes as described in Table I. Molecular mass and charge 
(pI) were calculated  for each peptide with the MacProMass'- program (S. 
Vemuri and T. D. Lee, Beckman Research Institute, Duarte, CA). 
After synthesis,  peptides were purified by preparative HPLC on either 
C-18 (Vydac) or PRP-3 columns (Hamilton; Reno, NV), as described by 
Lane and Sage (1990). Hydrophilic peptides that were not retained on C-18 
or PRP-3 columns were purified by high performance hydrophilic interac- 
tion chromatography on polyhydroxyethyl  aspattamide columns (POlyLC; 
Columbia, MD). Samples were applied to polyhydroxyethyl aspartamide in 
80% CH3CN/15 mM ammonium formate (pH 2.7) (buffer A), and peptides 
were eluted with a linear gradient of buffer B (30% CH3CN in 15 raM am- 
monium formate at pH 2.7). Peptides purchased from commercial sources 
were analyzed for purity by HPLC or hydrophilic interaction chromatogra- 
phy and were used as provided by the manufacturer.  Sequences of peptides 
made for this study were verified by amino acid analysis  after hydrolysis 
in 6 N HC1 (Dr. S. Kumar, Dept. of Biochemistry,  University of Washing- 
ton) and by mass-spectral analysis.  Purified peptides  were  lyophilized 
repeatedly  to remove salts before use in cell culture.  Peptides were soluble 
in physiological buffers, and the concentrations of stock solutions were de- 
termined by amino acid analysis.  Concentrations of SPARC protein were 
calculated based on its absorbance at 280 rtm and an extinction coefficient 
(Eo.I%; tem) of 0.82 (Lane and Sage,  1990). 
Cell Culture 
Bovine aortic endothelial (BAE) cells were cultured in DME with 10% fetal 
bovine serum, 250 mg/ml amphotericin B, 100 U/rnl penicillin G, and 100 
U/ml streptomycin sulfate,  as previously  described (Iruela-Arispe  et al., 
1991a). Cells from cultures predisposed to cord formation (defined herein 
as  angiogenic  cultures)  were  cloned and pessnged  with trypsin-EDTA. 
Nonangiogenic  BAE cells (i.e., cells that maintained a contact-inhibited 
monolayer and never formed cords or robes) cultured under identical condi- 
tions were used as controls.  Experiments were performed with clones be- 
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Name*  Sequence§  MassU  Activity¶ 
4-23  QTEVAEEIVEEETVVEETGV  2,219.3  - 
54-73  CQNHHCKHGKVCELDESNTP  2,279.5  - 
55-64c59-s  QNHHsKHGKV  1,170.6  ND 
64-73  VCELDESNTP  1,105.5  ND 
113-130  TLEGTKKGHKLHLDYIG  1,910.2  + + + + 
113-128  TLEGTKKGHKLHLDY  1,740.0  +  + + + 
113 - 1301t121-R  TLEGTKKGrKLHLDYIG  1,938.2  ND 
113-130K119-A  TLEGTKaGHK  HLDYIG  1,853.1  ND 
119-122  KGI-IK  469.3  +  + + + 
119-122m21-R  KGrK  488.3  + 
119-122m2s-A  KGaK  403.3  + 
120-122  G HK  ,  341.2  + 
154-173  KNVLVTLYERDEGNNLLTEK  2,348.6  - 
184-203  NEKRLEAGDHPVELLARDFE  2,466.7  ND 
254-273  TCDLDNDKYIALEEWAG-CFG  2,263.5  - 
* Peptides were synthesized based on the published amino acid sequence of murine SPARC, as described in Materials and Methods. 
Peptide names are derived from their position within the wild-type sequence of SPARC after removal of the signal sequence. 
§ Amino acid residues are indicated by their single letter codes, and Cys (C) residues are highlighted in bold face type. The sequence GHK is highlighted  with 
a double underline. An inversion of this sequence, KHG, is found in peptide SPARC~3 and has been highlighted  with a single underline. Alterations of wild- 
type sequences were synthesized  and served as controls. Substituted  residues are shown as lower case letters in the sequence, and the substitution  is indicated 
as a subscript in the name. 
II Mass (in atomic mass units, D) was calculated  by the MacProMass  TM program. 
ql Angiogenic activity was assessed by bioassays in vitro as described in Materials  and Methods. Peptides were added in serum-free DME (final concentration 
was 125/~M),  and cord formation was measured after 4 d. Results are summarized  as active (+) or inactive  (-). ND, not determined. 
twcen passages 9 and 17. As noted in the text, some experiments wen: car- 
tied out with DME supplemented with CuSO4 and BSA. The BSA (a gift 
from E. Raincs, Department of Biochemistry, University of Washington) 
was tested before use in these experiments, and was found to be free of 
platelet-derived growth factor, transforming growth factor-beta, and other 
mitogens that display activity in a 3T3 cell proliferation assay. 
Quantitation of Cord Formation 
The use of cloned BAE ceils that form cords and tubes (a process termed 
angiogenesis in vitro) for the analysis of potentially angiogenic proteins has 
been previously described (Iruela-Arispe et al.,  1991c).  Angiogenic BAE 
cells were passaged, plated in 15.5-mm diameter tissue culture wells, and 
cultured in DME with 10% fetal bovine serum. Experiments were initiated 
after cords were evident (7-10 d). Cultures were preincubated in serum-free 
DME for 24 h and subsequently with DME with or without peptides for 
the times indicated. Cells were treated for 1-4 d with increasing doses of 
the test substance. Medium and fresh reagents were changed every 24 h. 
At 24-h intervals, photomicrographs that represented the projected image 
of these cultures were taken from randomly selected fields (500/~m  2) of 
each plate with an inverted phase-contrast photomicroscope. The number 
of  cords  was assessed  by  counts  of  cord  intersections  in  a  microscopic  field, 
as described by Iruela-Arispe et al. (1991c). Changes in cord number were 
assessed in the same field of each well on successive days of culture. The 
number of cords present at the beginning of the experiment was taken as 
100%. Experiments were performed in triplicate. Upon completion of the 
experiment, cultures were fixed and embedded for further morphometric 
analysis. 
CAM Angiogenesis Assays 
Methylcollulose, a sustained drug-release matrix, was polymerized with so- 
lutions of SPARC,  various  synthetic peptides, or other test compounds. 
Disks were prepared by combination of equal volumes of test solution (in 
PBS) with 0.5 % methylcellulose  (400 centipoises; Sigma Chemical Co., St. 
Louis,  MO). The mixture  was placed  on Teflon  and  dried  slowly  overnight 
at room temperature under sterile conditions. Fertilized white Leghorn 
chicken eggs (Biological Supply, Lynnwood, WA) were incubated at 37°C 
in 60% relative humidity. On day 3, eggs were opened carefully into petri 
dishes. Embryos with intact CAMs and yolks were cultured in an humidified 
tissue culture incubator at 37°C,  1-3% CO2 under sterile conditions; no 
culture medium was used. The culture method was essentially as described 
by Auerbach et al. (1974).  After 8 d of culture (embryonic day 11; stage 
28-30  [Hamburger  and  Hamilton,  1951]),  methylcellulose disks  were 
placed on the periphery of the exposed surface of the CAMs; the area 
(nearly one fourth of the CAM) nearest to the embryo was not used. Disks 
were  then  incubated  for  various  times  before  the  CAMs were  photographed 
under a  dissecting photomicroscope. All treatments were performed in 
duplicate on at least four different CAMs. Substances with known activity 
in this assay were applied to each CAM as controls: PBS buffer (a neutral 
compound), basic fibroblast growth factor (bFGF; a  stimulator of blood 
vessel formation), and protamine (an inhibitor of blood vessel formation) 
(Taylor  and Folkman,  1982). 
Copper-immobilized Metal Affinity 
Chromatography (Cu-IMAC) 
SPARC  protein  and  peptldes  were  soiubilized  in  buffer  A  (0.02  M 
NaH2POa  at pH 7.0, 0.5 M  NaCI) and applied to a  75  ×  8-ram HPLC 
column (Chelate-5 PW; TosoHAAS, Philadelphia, PA) previously charged 
with CuSO4 and equilibrated in 40% buffer B (0.1 M NaI-12PO3 at pH 2.8, 
0.5 M NaCI) at a flow rate of 1 ml/mln. The pH of the eluate at 40% buffer 
B was 6.0. Eluate was monitored at an absorbance of 214 nm. As a control, 
peptides were applied to the column in the absence of bound metal. Under 
these conditions, all peptides eluted within the void volume of the column; 
no binding was detected. The column was routinely stripped with ED'rA 
to remove residual contaminants and was recharged with fresh CuSO4. 
Electrospray Mass Spectrometry 
The molecular weights and amino acid sequences of peptides purified from 
SPARC digests or of synthetic peptides used in these experiments were de- 
termined by electrospray-mass spectrometry by continuous infusion of sam- 
ple into a triple quadrapole instrument (SCIEX API Ill; SC1EX, Thornhill, 
Ontario,  Canada) equipped with a  nebulization-assisted elcctrospray ion 
source (Covey et al., 1988; Fenn et al., 1989).  Ions of interest were further 
characterized by tandem mass spectrometry, a technique in which peptides 
from a complex mixture can be isolated as individual precursor ions by the 
first of tva) mass analyzers and subsequently fragmented by collision with 
argon gas. The resulting fragments represent an overlapping series of ionic 
dipeptides, tripeptidas, etc., which are then identified by a second mass ana- 
lyzer. The  amino  acid  sequence  can  be  deduced  from  the  observed  fragmen- 
tation  patterns  (Hunt et  al.,  1986).  With  additional  information,  in  this  case, 
the  known amino acid  sequence of SPARC and synthetic  peptides  used as 
controls,  the  derived  amino acid  sequence data  are  unambiguous. Polypro- 
pylene  glycol  and whale myoglobin served  as  calibration  standards.  Masses 
of  parent  and  product  ions  deviated  by  <0.5 D from  their  theoretical  values. 
Copper-binding Studies 
Water for binding studies was filtered and deionized with a muiticartridge 
deionizing unit;  final resistance was >15  Mfl.cm  -1  at 25°C (Milli Q~'; 
Lane et al. Angiogenic Peptides of SPARC  931 Millipore Corp., Bedford, MA). Stock solutions of buffers and monovalent 
ions were treated with resin (Chelex  TM  100; Bio Rad Laboratories, Rich- 
mond; CA), prepared as described (Walsman and Rasmussen,  1983), to re- 
duce trace metals. Calibrated stocks  of divalent cations were purchased 
from J. T. Baker, Inc. (Phillipsburg,  NJ). Binding studies were carried out 
in 20 mM NaHCO4 (pH 7.4) at room temperature (22-25°C). Copper and 
magnesium stocks were diluted as indicated in the figure legends.  Cop- 
per:peptide complexes  were analyzed by electrospray  and tandem mass 
spectrometry.  The sequences of pepfides  present in peptide:Cu  2+ com- 
plexes were verified  by analysis of daughter ions generated by fragmentation 
of the parent complex as described above. Before analysis of Cu2+-binding 
peptides,  the silica sample introduction line was flushed with EDTA to re- 
move contaminating divalent ions. 
Proteolytic Cleavage and Analysis of  Released Peptides 
SPARC or synthetic  peptides were solubilized in "IS buffer (50 mM Tris HCI 
at pH 7.5, 150 mM NaCI)  and digested  with enzymes for the times in- 
dicated.  After protvolysis,  samples  were  lyophifized  and  analyzed by 
hydrophilic  interaction chromatography,  as described above, or by PAGE. 
For SDS-PAGE, peptides were solubilized in sample buffer, heated at 95°C 
for 3 rain with or without 5 mM dithiothreitol, and separated'on 10-20% 
gradient minigels (Dalichi Pure Chemicals, Tokyo, Japan) with a Tricine- 
SDS buffer system (Schigger and yon Jagow, 1987). Gels were fixed for 5 
rain in 1% glntaraldehyde,  stained with Coomassie brilliant  blue, destalned, 
and dried. Dried gels were photographed directly or exposed to autoradio- 
graphic film (X-OMAT, AR; Kodak, Rochester, NY). For hydrophilic inter- 
action chromatography,  the absorbance of the eluate was monitored at 214 
nm, and peaks of absorbance were lyophilized for mass spectral analysis. 
Controls included incubation of enzyme in the absence of substrate.  Chro- 
matography of synthetic peptides was used to calibrate the system,  and 
blank runs were performed to insure that carryover of peptide fragments did 
not occur between chromatography runs. For PAGE analysis of SPARC, na- 
.125  live protein was labeled with Nal  I] and chloramine-T as an oxidant (final 
specific  activity was  ,~200 cpm/fmol SPARC) (Hunter and Greenwood, 
1962). Enzymes for analysis of  protein cleavage patterns were of sequencing 
grade and included bacterial collaganase,  form HI (Advance Biofactures 
Corp., Lynbrook, NY), bovine pancreatic elastase (Cooper Biomedical, 
Malvern, PA), prostromelysin (gift of Drs. A. Strongin and G. Goldberg, 
Washington  University,  St.  Louis,  MO),  bnman thrombin (gift  of Dr. 
W. Kisiel,  University of New Mexico,  Albuquerque, NM),  and bovine 
pancreatic  trypsin-TPCK  (N-tosyl-L-phenylalanine  chioromethylketone) 
(Worthington Biochemical Corp., Freehold, NJ). Human plasmin, human 
Factor X, and Russell's viper venom, used for the activation of Factor X, 
were the kind gifts of Drs. J. C. M. Meijers (University of Utrecht, The 
Netherlands) and K. Fujikawa (University of Washington).  Human Factor 
X was activated  with Russell's  viper venom as described (Meijers et al., 
1987), and prostromelysin was activated with  p-aminophenyl-mercuric  ace- 
rate as described (Cawston and Murphy,  1981). 
Sequence Analysis 
Sequence analysis  and searches for specific  sequence motifs  were per- 
formed with the SwissProt data base (Release  22.0), with the aid of the 
FIND program contained within the University of Wisconsin Genetics 
Computer Group sofi~are packege  (version 7.1) (Devereux  et al.,  1984). 
The software  was maintained and operated through the Locke computer 
center at the University of Washington. 
Results 
Expression of  SPARC in Endothelial Cells Exhibiting 
Angiogenesls In Vim 
Analysis of SPARC expression in endothelial ceils is compli- 
cated by the small amounts of cytoplasm in these cells and 
the potential for expression by adjacent cells. Therefore, we 
looked for expression in the cerebral cortex of embryonic 
mice and in adult dermis after wounding; both brain and skin 
characteristically exhibit high levels of angiogenesis and low 
levels of endogenous SPARC  expression  (Holland et al., 
1987; Reed et ai., 1993).  Fig. 1 A shows the expression of 
SPARC mRNA in the vasculature of the developing brain 
of a  17-d-old mouse embryo. Probes from the sense strand 
of DNA did not hybridize to cellular mRNA under identical 
conditions (Fig. 1 B). The distribution of positive cells was 
identical to, but more restricted than that of cells stained 
with the 134 lectin from R simplicifolia (BSLB4) (Fig. 1 D), 
a marker of murine endothelial cells (Coffin et al., 1991). To 
determine whether the capillary endothelial cells were pro- 
liferating, we stained serial sections from the same embryo 
with antisera against PCNA and the 154 lectin (Fig. 1, E and 
F, respectively). PCNA antisera reacted with a subset of en- 
dotbelial cell nuclei (compare localization of signal between 
Fig. 1, E and F), a measure that angiogenesis was ongoing 
at this time of development. Since the requirements for anti- 
gen preservation are different, it was not possible to detect 
SPARC protein and PCNA simultaneously in these sections. 
The data thus provide evidence that both SPARC mRNA and 
protein are expressed by endothelial cells undergoing de- 
velopmental angiogenesis. In contrast, SPARC was not seen 
in the endothelium of large vessels, such as the aorta, at this 
time or in mature brain capillaries later in development, but 
it was present in some vascular smooth muscle cells,  as 
reported by Wewer et al. (1988). Recent studies have shown 
that a second endothelial gene, yon W'dlebrand factor, is also 
differentially  expressed in capillaries (Coffin et al., 1991). It 
is,  therefore, possible that expression of SPARC  is  tem- 
porally regulated during vessel maturation and subserves a 
function at specific stages early in this process. 
The distribution of SPARC protein was indistinguishable 
from that of the corresponding mRNA. Fig. 1 C shows the 
pattern of reactivity of an anti-SPARC peptide IgG in 17-d- 
old mouse embryonic brain. The reactivity was eliminated 
by incubation of the antiserum with the immunogen, a syn- 
thetic peptide representing amino acids 16-35 of the mature 
protein (not shown). Expression was not observed in all ves- 
sel profiles; however, positive vessels were visible at all lev- 
els of  the brain and were particularly evident near the menin- 
gial surfaces.  We detected SPARC  in a  subset of vessels 
throughout the development of the embryonic brain  (not 
shown). Vasculature of adult mice did not appear to express 
SPARC  protein  or  mRNA by  these  methods.  Cells  im- 
munoreactive for SPARC also appeared in dermal capillaries 
of  an adult rat 3 d after the area received a full-thickness inci- 
sional wound (Fig.  1, G and H). Capillaries in unaffected 
regions of the dermis appeared negative. 
SPARC and Peptides Derived  from 
SPARC11~I~o Stimulate the Formation of  Endothelial 
Cords In Vitro 
Addition of SPARC  to  cultures  of endothelial cells  that 
formed cords and tubes in vitro (i.e., angiogenic cultures) 
was associated with an increase in the number of new cords 
over 1-4 d of treatment. Fig. 2 illustrates the culture system 
and the  increased  sprouting  induced by incubation with 
SPARC (Fig. 2, C vs D). The number of cords was deter- 
mined by a count of cord intersections (branchpoints) within 
a  specific field (Fig.  3) according to a published method 
(Iruela-Arispe et al., 1991c). To control for the variation in 
cord number among individual culture wells, we normalized 
the counts to the number of cords present at day 1 for each 
well, and experiments were performed in triplicate. ~eat- 
The Journal of Cell Biology, Volume 125, 1994  932 Figure L  SPARC is expressed  in capillaries  of embryonic brain and in capillaries  of dermal wounds.  (A-F) 5-t~m sections of brain tissue 
from 17-d-old mouse embryos. (A) In situ hybridization of SPARC mRNA (antisense  probe). (B) Serial  section to A (sense probe). (C) 
Immunohistochemical localization of SPARC protein. (D) Histochemical identification  of endothelial  cells with the 134 leetin of B. sim- 
plicifolia. C and D do not represent serial sections.  (E) Immunohistochemical localization of  proliferating  cells with a monoclonal antibody 
against PCNA. (F) Same section shown in E, stained with the I34 lectin to identify capillaries.  (G and H) Immunohistochemical  localization 
of SPARC protein in full-thickness  rat dermal wounds (3 d after injury),  mRNA was detected by autoradiography of  tissues after hybridiza- 
tion with [35S]SPARC  riboprobe RNA. SPARC protein was identified  as a brown product after reaction with an affinity-purified  anti- 
SPARCI~.3~ antibody,  used with an avidin-biotin-peroxidase  detection system.  PCNA was detected with an FITC-linked secondary anti- 
body and a photomicroseope equipped with an epifluorescence  imaging system.  B4 leetin in D was labeled  with biotin and is visualized 
as a brown reaction product in conjunction with an avidin-biotin-peroxidase  detection system. 134 lectin in F was labeled with rhodamine. 
Small arrows, signal in capillaries;  double arrows, signal in medium-sized vessels;/arge arrows in A, signal that corresponds to meningial 
fibroblasts;  arrows in EandF, nuclei from proliferating  endothelial  cells.  *Additional immunopositive cells in granulation tissue that possi- 
bly correspond to fibroblasts  or maerophages.  Bars, 50/tin in A-F, 100 ~m in G and H. 
Lane et al. Angiogenic Peptides of SPARC  933 Figure 3.  Effect of SPARC and SPARCH3.13o  on the formation of 
endothelial cords. Clones of endothelial cells were grown until a 
network of  cords was established (10-14 d). The cells were cultured 
for an additional 24 h in serum-free medium. Peptides were added 
in fresh serum-free medium (day 1); photomicrographs were taken 
at 24-h intervals. Reagents  were replaced every 24 h. Counts of  cord 
intersections were made at identical positions for each dish, and 
values were normalized to the value obtained at day I for each well. 
Averages of triplicate determinations, +  SE, were plotted. 1, PBS 
control; 2, I0 ng/rni bFGF; 3, 750 nM SPARC (20/~g/ml); 4, 125 
/tM SPARCma3o (250.0/~g/ml); 5,  125/~M KGI-IK  (58.6 ttg/ml); 
6, 125 t~M KGAK (50.4/tg/mi);  7, 125/~M KGRK (61.0 ttg/ml); 
and 8, 125 #M SPARC54-73 (250.0/,tg/ml). 
Figure 2. SPARC increases the number of  cords produced by angio- 
genie endothelial cells in vitro. (,4) Photograph of several culture 
wells with angiogenic clones; (B) photo of  one weft. Before photog- 
raphy, ceils in A and B were fixed briefly in methyl-Carnoy's solu- 
tion and stained with 1% toluidine blue to demonstrate the inter- 
cormeeting  network  of  endothelial  cells.  (C  and  D)  High 
magnification photomicrographs  illustrating  the  differences be- 
tween unfixed cultures of  angiogenic BAE cells treated for  48 h with 
control saline (PBS) (C) or 20 ~tg/ml SPARC (D). Arrow in A, 
identifies locator ring, drawn on the bottom of each well, that al- 
lowed photography of  identical fields on successive days of  culture; 
arrows in B, Cand D, cords of  endothelial cells;/arge white arrows, 
thick cords; small white arrows, small cords prevalent in D. Bars, 
5 ram in A and B, 100 ttm in C and D. Diameter of 1 culture well 
is 15.5 ram. 
ment with SPARC resulted in a twofold increase in the num- 
ber of  cords within 2--4 d (Fig. 3, column 3). Treatment with 
bFGF, a known stimulator of angiogenesis in vitro and in 
vivo (Montesano et al.,  1986,  and references therein), was 
associated with a  similar increase (Fig. 3, column 2).  Ex- 
posure of angiogenic cultures to a variety of SPARC-derived 
peptides (Table I)  revealed similar angiogenic stimulation by 
a  synthetic peptide representing cationic region 2  (amino 
acids  113-130) of the Cys-rich portion of SPARC  (Fig.  3, 
column 4). Incubation of  cultures with peptides representing 
sequences from cationic region  1 (amino acids 54-73) or 
with bovine serum albumin had no stimulatory effect  and oc- 
casionaUy resulted in a  slight decrease in the number of 
cords  (Fig.  3,  column  8,  and  Table D.  Further  analysis 
demonstrated that a  sequence of four amino acids, KGI-IK 
(amino acids  119-122), contained significant activity (col- 
unto 5).  Substitution of the central His residue with Ala 
(column 6) or Arg (column 7) reduced the apparent stimula- 
tion. Further truncation of the active sequence resulted in a 
loss  of stimulatory activity in  this assay;  GHK had  little 
effect on the number of endothelial cords after 4 d; however, 
pretreatment of GI-IK  with  CuSO,  resulted in  significant 
angiogenic stimulation (not shown).  Since treatment with 
CuSO4  alone had a  minor stimulatory effect, we confined 
our analysis to KGHK and longer peptides that did not re- 
quire pretreatment to acquire activity. 
SPARCu~I~ and KGHK Specifically Stimulate 
Angiogenesis In Vim 
Peptides identified as stimulators of angiogenesis in  vitro 
were tested for their ability to induce angiogenesis in vivo. 
SPARC~3.13o (Fig. 4  C) and KGHK (Fig. 4 D) induced ex- 
tensive angiogenic responses within 24 h in the absence of 
exogenously supplied CuSO,.  The response resulted in  a 
characteristic radial pattern of both large and small vessels 
that culminated in a vascular knot at the center of the treated 
area. In contrast, SPARC~, did not generate a  significant 
response (Fig. 4 A), and disks that contained the substituted 
sequence KGRK elicited a very weak response (not shown). 
The angiogenicpeptide bFGF stimulated vessel formation to 
The  Journal  of  Cell  Biology,  Volume 125,  1994  934 Figure 4. SPARC113q30 and KGHK stimulate angiogenesis in the chick CAM. (A-D) Photographs of regions of the CAM after treatment 
with (A) SPARC54-73 (266#g), (B) bFGF (200 ng), (C) SPARC113-130 (222/~g), and (D) KGHK (30 #g).  Peptides were diluted in PBS 
and polymerized with methylcellulose to form slow-release disks. Disks were applied to the ectodermal surface of the chick CAM cultured 
ex ovo. CAMs were photographed after  24 h. Small  and large arrows,  radial vasculature that has developed within and outside the methylcel- 
lulose disks, respectively. Bars, 2 mm in A,  1 nun in B-D. 
an extent that resembled the response to KGHK, both in 
magnitude and in the radial arrangement of the vessels (Fig. 
4 B). Exposure to protamine, an inhibitor of vessel growth 
(Taylor and Folkman, 1982), resulted in the formation of an 
avascular zone (not shown). KGHK elicited angiogenic ac- 
tivity with applications as low as 50 ng/disk. Additional ex- 
periments have shown that the angiogenic effects of SPARC 
peptides were dose dependent and developed in the absence 
of  immune cells or macrophages (Iruela-Arispe, M. L., T. E 
Lane, D. Redmond, M.  Reilly, R. Bolender, T. Kavanagh, 
and E.  H. Sage, manuscript submitted for publication)i 
The effect  of  native SPARC protein on CAMs was variable. 
In  some experiments, there was  a  modest increase in the 
number  of vessels  and  in  the  appearance  of their radial 
growth toward the disk. However, the effect was not as evi- 
dent in other experiments. Because the disks are acellular, 
we tentatively concluded that direct cell contact, as provided 
by the assays in vitro, might be required for a more vigorous 
response.  Alternatively, SPARC  binds to a  number of ex- 
tracellular matrix components and might not diffuse into the 
tissue effectively. Another possibility is that SPARC must be 
degraded before cell contact to elicit an angiogenic response. 
Since mapping identified a  potential Cu2+-binding  domain 
in SPARC as a source of angiogenic activity, we wanted to 
determine whether this sequence bound Cu  2+, and whether 
Cu2+-binding  and angiogenic stimulation were independent 
activities. 
Two Cationic Regions of SPARC Represent 
Copper-binding Sites 
A previous study has shown that SPARC binds copper ions 
(Vernon  and  Sage,  1989).  Copper-binding  proteins  are 
known to accumulate at  sites of tissue repair and,  under 
some circumstances, to be angiogenic in vivo (Raju et al., 
1982). Therefore, it was important to determine whether the 
angiogenic activity of SPARC was related to Cu  2+ binding. 
Immobilized  metal  affinity  chromatography  (IMAC)  has 
been used on several :occasions to identify interactions be- 
tween proteins and divalent cations (Porath et al., 1975). Ini- 
tiai experiffients with SPARC  demonstrated that the native 
protein bound to  Cu~+-charged  IMAC  columns with high 
affinity. Retention of SPARC on these'matrices required the 
presence of immobilized metal,  but  the  protein  was  not 
released under several typical elution regimes (low pH, low 
ionic strength, and gradients of imidazole). Instead, efficient 
elution of SPARC required large, stepwise additions of im- 
idazole (Fig. 5, A and B) or EDTA. These results indicated 
that SPARC bound Cu  2+ with high affinity, and/or that mul- 
tiple sites on the protein combined to form a highly stable 
interaction with immobilized Cu  ~+. 
We decided to use this procedure to scan for SPARC pep- 
tides with CuZ+-binding capacity. Fig. 5 C shows the results 
of multiple analyses in which purified preparations of syn- 
thetic peptides were subjected to analysis by Cu4MAC. Pep- 
tides from both cationic regions of  the follistatin-like domain 
Lane et ai. Angiogenic Peptides of SPARC  935 Figure 5.  SPARC54-73 and SPARCu3.13o represent 
potential copper-binding domains in SPARC. Pu- 
rified SPARC protein (100 ~tg) was applied to an 
inlmobilized Cu2+-affinity  column (Cu2+-IMAC). 
Pooled fractions were collected as indicated, dia- 
lyzed, lyophilized, and assayed for the presence of 
SPARC protein. (.4) Schematic diagram of a typi- 
cad gradient profile from IMAC. (B) Results of an 
immunoblot of  proteins from each pooled fraction 
after resolution by SDS-PAGE. SPARC bound to 
the column  (fraction  1)  and  was  not  eluted by 
decreasing  pH  (fractions  2  and  3).  Release of 
bound SPARC required the addition of imidazole 
(50 mM) (a specific competitor for bound Cu  2+) 
(fraction 4). EDTA (a chelator of  divalent cations) 
was  used  to strip  remaining proteins  from the 
column (fraction 5). (C) l-raM solutions of syn- 
thetic peptides that represent several regions of  the 
SPARC protein were applied to Cu2+-IMAC and 
were eluted with a gradient of  decreasing pH. Pep- 
tides shown in chromatograms a, d, and f did not 
bind under the conditions used (pH 6.0). The re- 
lease of pepfide SPARClu.~ was retarded,  and 
the  peptide  was  subsequently eluted under  iso- 
cratic conditions (e). Peptides SPARCs,73 (b) and 
SPARCn3a3o (c)  were  retained  and  eluted  at  a 
pH of  4.85--4.95. SPARC and SPARC  peptides did 
not bind to these columns in the absence of im- 
mobilized copper (not shown). (D) Peptides with 
mutations within the proposed  Cu2+-binding re- 
gions  were  analyzed by Cu2+-IMAC, and  their 
elution patterns were compared with those of  wild- 
type sequences:  (g) SPARCn3.13o  and (h) a mu- 
tated version of SPARCII3-13o in which Hisl21 has 
been replaced by Arg. Chromatography of sam- 
ples in Cand D used a gradient of  increasing buffer 
B that resulted in decreasing pH: buffer A, 20 mM 
NaPOd0.5 M NaCI (pH 7.0); buffer B, 100 mM 
NaPOJ0.5  M NaCI (pH 2.7). Elution was moni- 
tored at 214 nm. 
(SPARC~, and SPARCn3-13o) (Lane and Sage, 1994) bound 
and were eluted with gradients of decreasing pH at similar 
positions (pH 4.85--4.95) (Fig. 5 C, profiles b and c). Pep- 
tides from other regions of the protein did not bind or inter- 
acted weakly with the resin, and peptides from the o~-helical 
domain UI failed to bind with high affinity (Fig. 5 C, profiles 
d  and  e).  The  delayed  elution  of  peptide  SPARCts,203 
resulted from a weak interaction with the column. Since this 
peptide also eluted at the same position when chromatogra- 
phy was performed under isocratic conditions (pH 6.0), the 
interaction  of  SPARCIw2~  was  most  likely  nonspecific. 
Peptides that coincided with the two previously character- 
ized  Ca2+-binding  domains  (SPARC~-23 and  SPARC2s4-2~3) 
failed to bind immob'dized Cu  2+ (Fig.  5  C, profiles a  and 
f). The formation of multiple peaks in the IMAC profile of 
SPARC54.73 appeared to result from alternate complexes be- 
tween the resin and the Cys residues in this peptide. When 
we tested a 10-amino acid peptide that included the first cat- 
ionic  sequence  (SPARCss-64c59-s, corresponding  to  amino 
acids 55-64 with a Ser residue in place of the Cys normally 
found at position 59), the peptide eluted as a single peak in 
a position similar to that of SPARCH3.t3o (not shown). 
To characterize further the amino acids involved in the 
binding of SPARCI13.13o  to immobilized Cu  2÷, we analyzed 
peptides with mutations in the cationic region by IMAC. In 
Fig. 5 D (profile g), SPARCII3.t3o  appears as an elution con- 
trol.  In profile h,  the elution of SPARC,3-t~a21.s is shown 
This peptide represents a mutated sequence in which Hisl21 
is converted to an Arg. SPARC113-13om2t.R  bound to the Cu  2+- 
charged resin but eluted considerably earlier in the gradient 
(pH 5.5) than did the wild-type sequence. These data indicate 
that Hisnl is important for Cu2+-b'mding activity within this 
sequence of SPARC,  but that other residues also appear to 
contribute to the affinity. 
It has  recently been recognized that  ionspray (or elec- 
trospray ionization) can be used for the study of peptide- 
metal interactions (Hutchens et al.,  1992).  Since peptides 
less  than  five amino  acids  in  length  did  not bind  Cu  2÷- 
IMAC, we used ionspray mass spectrometry (Covey et al., 
1988) to determine whether the fragments of SPARCH3-130 
used in the previous growth assays continued to associate 
with copper ions. As shown in Fig. 6 (A), the predicted mass 
of KGI-IK (468.3 D) is in good agreement with the observed 
value of the protonated molecule (MH  + =  469.3 D). After 
the  addition  of 50  #M  CuSO4  (KGHK:Cu,  1:2.5),  two 
peaks of mass/charge ratio 530.3 and 532.3 were observed. 
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Figure 6. Demonstration of Cu  2+ binding by isolation of the Cu  2+- 
KGHK complex.  20 tiM solutions of KGHK were prepared in 20 
mM NH4HCO3 (pH 7.5) and were analyzed by mass spectrometry. 
The masses of relevant ions are indicated. (.4) KGHK alone (MH  + 
=  469.3).  (B) KGHK +  50/~M CuSO4: the 469-D ion seen in A 
is absent and a doublet of 530.3/532.3 D has appeared ([KGHK + 
Cu  -  H]+; 63Cu and 65Cu appear in the expected isotopic ratio). 
Since the KGHK/Cu spectra show no evidence of free KGHK, a 
conversion of 100% to KGHK:Cu complexes is indicated. KGHK 
was  also  treated  with  50  tiM  MgSO4 (C).  The presence  of a 
530-D ion (KGHK:Cu; 1:1) in C indicates that residual copper ions 
were bound in the presence of excess Mg. (D) Results of a direct 
competition between KGHK (MH  + = 469.3) and KGRK (MH  + = 
488.5) for copper ions present in limiting amounts. 10-tiM peptides 
were mixed with 8/xM Cu  2+. The resulting  spectra demonstrate 
that a KGRK:Cu complex was not formed ([KGRK +  Cu -  HI  + 
= 550.5), and that all copper ions were sequestered in a KGHK:Cu 
complex ([KGHK  +  Cu  -  HI  + =  530.3/532.3). 
These ions are consistent with KGHK (468.3) and with the 
complex (peptide+Cu-H)  + that contains both ~Cu and eCu 
in the expected isotopic ratio.  Thus,  KGHK formed a  1:1 
complex with copper ion (Fig. 6, A vs B). Similar 1:1 com- 
plexes did not form with equivalent amounts of another diva- 
lent  cation,  magnesium  (Fig.  6  C).  Interestingly,  a  trace 
amount  of  KGHK:Cu  2+  complex  could  be  identified  in 
buffers that lacked exogenously supplied  salts (Fig.  6  A). 
This complex was not displaced by 50 tLM Mg  2+ (a result 
confirmed  by  comparison  of peaks  at  mass/charge  ratio 
530.2 in A and C at higher resolution; not shown). Substitu- 
tion of the His residue with either Arg or Ala eliminated high 
affinity  Cu2+-binding.  In D,  KGHK and  KGRK were  al- 
lowed to compete for limiting amounts of copper ions. The 
figure demonstrates  that  the available Cu  2+ was bound by 
KGHK.  Additional  experiments  conducted  with  KGRK 
alone demonstrated that binding  of Cu  2+ did not occur at 
equimolar  ratios  of Cu  2+  and  peptide,  and  that  variable 
results were obtained at higher ratios of Cu  e+ (not shown). 
Figure 7. SPARe is degraded by platclet releasate and extraceUular 
serine proteases.  (A) nsI routine  SPARe  was incubated at 37"C 
with buffer (lane 1, C), a releasate from thrombin-activated human 
platelets (lane 3, P), or platelet relcasate that contained PMSF, a 
broad-spectrum  serine protease inhibitor  (lane 2, PI). Addition of 
EDTA increased  the degradation  of SPARe  in platelet  releasate 
(lane 4, PE). (B) [mI]SPARC isolated from humatl platelets was 
incubated with buffer (lane 5, C), trypsin 0ane 6, T), trypsin with 
PMSF (lane 7, T0, elastase (lane 8, E), bacterial collagenase (lane 
9,  Ca),  subtilisin (lane 10, Su),  or Factor Xa (lane 11, Xa).  (C) 
[1~I]SPARC isolated  from human platelets  was  incubated  with 
buffer (lane 12, C), plasmin (lane 13, Pl), or stromelysin (lane 14, 
St). Enzyme-to-substrate molar ratios were <1:100 and all reactions 
contained excess BSA as an intern~ control (not shown). Digests 
were resolved by SDS-PAGE on a 10-20% gradient gel. The posi- 
tions of protein (Mr X 10  -3) standards are indicated on the right. 
Fragmentation of the Cu:KGHK complex resulted in the re- 
lease of daughter ions consistent with a Cu:KGHK complex. 
Cu  2+ remained associated with peptide fragments through- 
out the  analysis.  The  smallest complex detected  included 
Cu:GH in a  1:1 molar ratio. 
To confirm these results,  we carried out a  spectroscopic 
analysis of SPARC,  SPARCm.t3o,  and KGHK. Addition of 
copper ions to the intact protein or to the peptides resulted 
in an increase in absorbance at 580 nm.  This binding was 
saturable and was not displaced with  100-fold excesses of 
Na, K, Ca, or Mg ions (not shown). In conjunction with the 
Cu2+-IMAC  analysis,  these results  support the  conclusion 
that Ca  2+- and Cu2+-binding  sites in SPARe are functionally 
independent. 
SPARC is Degraded by Extracellular Proteases 
To address the potential for proteolysis of SPARC in extracel- 
lular fluids associated with wound repair, we analyzed the 
effects of activated human platelet releasate on the stability 
of native SPARe.  Fig.  7 A (lane 3) shows that [t2sI]SPARC 
was degraded by human platelet releasate, and that the activ- 
ity was inhibited (lane 2) by PMSF, a broad-spectrum inhibi- 
tor of serine protease activity. SPARe was relatively stable 
to thrombin (Sage et al.,  1984), which is routinely used for 
the activation ofplatelets, but was degraded to low molecular 
weight components after exposure to freshly isolated platelet 
Lane  et al.  Angiogenic Peptides of SPARC  937 releasate. Since platelet releasate contains SPARC, we ana- 
lyzed immunoblots of proteins from similar releasates for 
evidence of proteolytic activity directed against the endoge- 
nous protein.  These experiments showed that endogenous 
platelet SPARC wasxapidly degraded into fragments similar 
in size to those produced from the iodinated exogenous pro- 
tein (not shown). We chose iodinated SPARC for routine as- 
says because more fragments could be analyzed by radiogra- 
phy,  in  comparison  to  immunoblotting that  would  have 
required peptide-specific antisera. Staining of the gels with 
Coomassie blue showed that many of the proteins present in 
the releasates were undegraded. Treatment of the platelet 
releasate  with EDTA,  a  chelator of divalent cations,  in- 
creased the extent of SPARC degradation (lane 4), a result 
which indicated that metalloproteinases were not required 
for the activity. 
We exposed iodinated SPARC to a variety of purified pro- 
teolytic enzymes and analyzed the pattern of  degradation. As 
shown in Fig. 7 B (lane 6), trypsin degraded SPARC to com- 
ponents of low molecular weight; the activity was inhibited 
by PMSF (lane 7). Elastase (lane 8) released a stable frag- 
ment of '~40 kD, whereas bacterial collagenase (lane 9) and 
clotting Factor Xa (lane 1/) had minimal or no effect. Subtili- 
sin (lane 10), a broad-spectrum serine protease related to 
mammalian dibasic endoproteases (Barr,  1991), and stro- 
melysin, a matrix-degrading metaUoprotease (lane 14), also 
degraded  SPARC. The  specificity of these  reactions  was 
monitored by addition of a 100-fold molar excess of BSA to 
the reactions. SPARC was preferentially degraded over BSA 
by all enzymes tested (not shown). 
Plasmin, a  serine protease related to trypsin and impli- 
cated in a variety of processes associated with angiogenesis, 
degraded SPARC to low molecular weight components (Fig. 
7, lane 13; Sage et al., 1984). Inclusion of EDTA augmented 
the susceptibility of SPARC to plasmin (not shown). The en- 
hanced degradation of SPARC  in  the presence  of EDTA 
indicated that local changes in the concentration of metal 
ions (presumably Ca  2÷ or Cu  E+) could alter the stability of 
SPARC to proteolysis. Similar effects of divalent cations on 
the susceptibility of SPARC to degradation have been de- 
scribed for several other proteinases (Maurer et al.,  1992). 
Proteolysis of SPARC Leads to the Release 
of KGHK and GHK 
Analysis of peptides  released from SPARC  demonstrated 
that  the  dibasic  amino  acid  sequence  -KK-  at  position 
117-118 was susceptible to cleavage by both trypsin and plas- 
min. Fig. 8 shows the elution profiles from hydrophilic inter- 
action  chromatography  of  SPARC  (C)  and  the  peptide 
SPARCH3-130 (B) after digestion with trypsin. Mass spectral 
analysis of the fractions eluting at 23 min revealed that the 
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Figure 8. Digestion of SPARC and SPARCu3.,a0  with trypsin releases peptides containing GHK. SPARC (6 nmol), or a synthetic peptide 
that spans amino acids 113-130 (200 nmol), was treated with trypsin (1:100, enzyme/substrate  molar ratio) for 2 h at 37°C. The solutions 
were lyophilized  and chromatographed on reverse-phase HPLC; unbound fractions were collected (not shown). (A, B, and.C) Hydrophilic 
interaction chromatography of peptide fractions; peptides were duted with gradients of acetonitrile. In A, synthetic GHK (88 nmol) was 
chromatographer as a standard. In B and C, the unbound fractions of digested SPARC and SPARCH3-13o  were analyzed by hydrophilic in- 
teraction chromatography. Fractions during at 23 min contained GHK by tandem mass spectrometry (not shown). The second peak in 
the digest of peptide 113-130 (B), at 26 rain, was identified as KGHK (not shown). (D, E, and F) Tandem mass spectrometry profiles 
of 3 #mol SPARC after treatment with trypsin (D), 3 #mol GHK (E), and a hydrolysis  control with trypsin alone (F), respectively. The 
masses (in atomic mass units [D]) of product ions released by ionization of the 341 + 0.5 D parent ion are shown. 
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340.2  D)  was  present.  KGHK  (SPARC,~m;  calculated 
atomic mass = 468.6 D) was found in fractions of  the peptide 
digest that eluted at 26 rain (B). KGHK was seen in variable 
amounts; extended digestion times resulted in a decrease in 
the amount of KGHK and a subsequent increase in GHK. 
For samples that contained  low amounts of SPARC, the 
use of hydrophilic interaction chromatography was required 
to remove salts from the peptides before mass spectrometry. 
However, GHK could be  identified directly by mass spectral 
analysis of the entire digest when larger amounts of protein 
were studied. Fig. 8, D, E, and F, show tandem mass spectra 
of unfractionated digests. Tryptic cleavage of SPARC (Fig. 
8 D) released a peptide (MH+), with a mass/charge ratio of 
341, which fragmented in a manner identical to that of the 
GHK standard (E). The pattern of product ions was com- 
pletely consistent  with the identification of GHK in these 
samples. Control digests in which the substrate was omitted 
(Fig.  8 F) or of SPARC in the absence  of enzymes (not 
shown) did not produce  ions of this type.  These controls 
demonstrate that GHK was not present as a contaminant in 
the initial preparations. 
Mapping of  Potential Proteolytic Sites for Plasmin 
and Trypsin 
The activity of  purified proteases on the two cationic regions 
of SPARC encompassed by domain II was analyzed by incu- 
bation of enzymes with peptides that represented these se- 
quences.  As  an initial  screen  for pmtease-sensitive  sites 
within SPARC, peptides that represented both cationic sites 
were exposed to proteolytic enzymes for 1-2 h and were ana- 
lyzed by high resolution gel electrophoresis. The results of 
these  experiments  are  shown  in  Table II.  The  peptide 
SPARC,3.13o was digested completely by exposure to either 
trypsin-TPCK or plasmin  (Molar  ratio of enzyme to sub- 
strate was <1:100). The same peptide was resistant to similar 
concentrations of  activated thrombin, Factor Xa, or bacterial 
coUagenase. A substituted peptide sequence in which Lys,9 
was replaced  by Ala (SPARC.3.~rj~9~ Table I) was more 
resistant to trypsin than was the wild-type sequence and was 
poorly cleaved by plasmin.  These results indicate that the 
-ILK- sequence is required for efficient recognition and cleav- 
age by plasmin. Comparable digestion of SPARC~3, which 
contains  an inverted KGHK site (IG-IGK; SPARC~), re- 
quired  higher  doses  of trypsin and appeared  resistant  to 
plasmin. 
Mapping of  enzymatic cleavage sites was accomplished by 
hydrophilic interaction chromatography. Tandem mass spec- 
trometry was used to confirm the sequences of the proteo- 
lyric  fragments identified  by  hydrophilic  interaction  chroma- 
tography.  In Fig.  9 A, the elution  profile  of  SPARC.~.t27 is 
shown after  digestion  with plasmin  or trypsin.  Undigested 
controls  are  presented  in  Fig.  9 B for  reference.  A summary 
of observed  cleavage sites  within both cationic regions 
(SPARC~.  and SPARCu3.~27) is presented as a schematic 
diagram  in Fig.  9  C. Cleavage of SPARCm.t27 resulted in 
fragments consistent with cleavage after the KK dibasic se- 
quence (after K.9). Trypsin also cut efficiently between the 
K residues (after Kin) and after GHK (Kin). The fragments 
recovered from the chromatographic  analysis of the tryptic 
digest  were consistent  with release  of KGHK and GHK. 
Plasmin cleaved peptide bonds COOH-terminal to Ktts and 
Table II. Enzymatic Susceptibility of Peptides  from Basic 
Regions of SPARC* 
Enzyme  SPARCu3-130  SPARCI1~.t~n~A  SPARC~.73 
Trypsin  High* (5)  Moderate (2)  Low (3) 
Plasmin  High (4)  Low  (2)  Stable (3) 
Thrombin  Stable (4)  ND  ND 
Factor Xa  Stable (2)  ND  ND 
Bacterial collagenase  Stable (2)  ND  ND 
Elastase  Moderate (3)  ND  ND 
* 20 ttg of peptide (see Table I for complete sequences) was digested with 1/~g 
of enzyme (enzyme to substrate molar ratios were <1:I00), and aliquots were 
removed for analysis on SDS-PAGE as described in Materials and Methods. 
Digestion was for 2 h  in Hepes-butfered saline, pH 7.5,  10 mM CaCI2,  at 
37°C. 
* Degree of activity was assessed by the loss of Coomassie blue-stained pro- 
tein: high, 90-100% reduction in stained protein; moderate, 40-60%  reduc- 
tion;  low,  10--20%  reduction;  stable,  no  evidence of reduction;  ND,  not 
determined. The number of experiments is indicated in parentheses. 
Kin, but the appearance of these products in low yield indi- 
cated  that the reaction  was considerably  slower than that 
observed  with  trypsin.  The  fragments  recovered  from 
hydrophilic interaction  chromatography  of the plasmin di- 
gest were consistent  with release  of an NH2-terminal se- 
quence and of KGHK and GHK in lower yields. 
Analysis  of the  digestion  products  of SPARC54_, indi- 
cated that this region was not cleaved by plasmin and served 
as a very inefficient substrate  for trypsin (summarized  in 
Fig. 9 C). 
Discussion 
In  this  study,  we  have demonstrated  the coincidence  of 
SPARC with endothelial reorganization in vivo and provided 
evidence that SPARC protein functions to support the growth 
of new vessels.  SPARC was shown to be expressed tran- 
siently and specifically in nascent capillaries during a period 
of rapid angiogenesis in the embryonic brain and in healing 
dermal wounds. Moreover, addition of SPARC to cultures of 
endothelial cells undergoing angiogenesis in vitro resulted in 
an  increased  number  of cords,  an  effect  mimicked  by 
synthetic  peptides  from  cationic  region  2  of  SPARC 
(SPARCH~130), a sequence that we show binds copper ion. 
SPARC,3_~30 and  smaller  peptides  derived  from this  se- 
quence were also shown to be potent stimulators of anglo- 
genesis in vivo, but a second Cu2+-binding peptide  (from 
cationic region  l) had no effect. Substitution of the amino 
acid Hism with either Arg or Ala decreased Cu  2+ binding 
and diminished the stimulation. Proteolysis of SPARC, or of 
synthetic  peptides  that overlapped  amino acids  113-130, 
resulted in the release of the peptides KGHK and GHK. 
Detection of  gene transcription by endothelial cells in vivo 
can be difficult, since these cells are characterized  by low 
amounts  of cytoplasm  and correspondingly  low levels of 
mRNA. Therefore, we decided to look for SPARC in tissues 
in which both endothelial migration and proliferation were 
enhanced, and in which the levels of SPARC expression in 
adjacent cell types was thought to be low. This strategy al- 
lowed us to detect expression in capillary endothelial cells 
from embryonic brain and from adult skin in response to 
wound repair. Our results indicate that SPARC is synthesized 
by endothelial cells in vivo and that principally growing or 
differentiating cells are implicated. Differential synthesis of 
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Figure  9.  Identification of  proteolytic  cleav- 
age  sites  in  synthetic peptides. (,4) Peptide 
SPARCII3.127 was  tre.ated  with  either  trypsin 
(1:300, enzyme/substrate molar ratio) or plasmin 
(1:100, enzyme/substrate molar ratio) at 37"C for 
2 h. Digests  were resolved on an hydrophilic  inter- 
action chromatography column developed with a 
gradient of acetonitrile. (B) Chromatograms of 
nndigest~l peptide (control) and synthetic  peptide 
standards (KGI-IK  and GHK). Peaks  of  absorbance 
(214 run) were collected for sequence analysis by 
mass spectrometry, and the mass of each peptide 
is indicated in parentheses next to each relevant 
peak. Lower case letters, elution positions of the 
fragments presented in C. (C) Schematic of the 
SPARC sequence shows the location of observed 
cleavage sites in  SPARC54-73 and  SPARCm-t27; 
lower case letters, peptide identified in the chro- 
matograms shown in A;/arge and small arrows, 
major and minor cleavage sites, respectively.  The 
sequence representing poptide SPARC54-73 was 
unaffected  by plasmin, and treatment with trypsin 
resulted in very low rates of cleavage (not shown). 
SPARC might reflect one means by which the availability of 
the protein is regulated during the response of endothelial 
cells to angiogenic signals. 
We have shown that an assay of endothelial cord formation 
in vitro produced results with SPARC peptides that were con- 
sistent with those obtained from a CAM assay in vivo. Al- 
though SPARC inhibits the proliferation of cultured, sub- 
confluent endothelial ceils (Funk and Sage, 1991, 1993), the 
present study is consistent with the hypothesis that SPARC 
and/or certain SPARC peptides can enhance the angiogenic 
response in vitro. Angiogenesis can be viewed as a series of 
interactions between endothelial ceils and their immediate 
extraceHular matrix; e.g., the production of matrix-degrad- 
ing proteases, acquisition of an invasive phenotype, exten- 
sion of endothelial cords, formation of patent capillary net- 
works, reestablishment of a basement membrane, and the 
return to a quiescent state (Folkman and Klagsbrun, 1987; 
Ingber and Folkman, 1989b).  The ability of growth factors 
to modulate this process presumably relies on their interven- 
tion at specific steps in the pathway, since these proteins can 
interact with several cell types, bind to various ligands in the 
extracellular milieu, or recruit inflammatory cells that re- 
lease  secondary  growth  stimulators.  Proliferation  assays 
can, however, be misleading (Sholley, 1984; Williams et al., 
1989) because not all steps in the process of capillary forma- 
tion are dependent on endothelial cell mitosis. Although cell 
proliferation in vitro remains the simplest and most fie- 
quently used  assay  for the  screening of angiogenic sub- 
stances, it is also instructive to study culture systems that 
present more complex interactions between endothelial cells 
and their extracellular matrix. 
SPARC has been described as a temporally regulated corn- 
portent of extracellular matrices. However, with the possible 
exception of bone and certain tumors, SPARC protein is not 
generally  observed  as  a  stable  extracellular component. 
SPARC has been shown to associate with extracellular ma- 
trices  and to regulate matrix deposition (Termine et al., 
1981; Romberg et al., 1986; Mayer et al., 1991; Lane et al., 
1992).  The effects of SPARC on ceils are consistent with a 
role in the regulation of ceil-matrix interactions: the protein 
is a potent inhibitor of  cellular spreading (Sage et al., 1989b; 
Lane and Sage, 1990) and has recently been shown to inhibit 
endothelial proliferation in vitro (Funk and Sage, 1991 and 
1993). Although SPARC has been characterized as a regula- 
tor of cell-substrate interactions (Sage and Bomstein, 1991), 
our observation that proteolysis of SPARC can lead to the re- 
lease of diffusable, bioactive peptides indicates that addi- 
tional functions should be considered. 
We have demonstrated that SPARC can be cleaved by plas- 
min and propose that other enzymes might also contribute 
to the release of KGHK and GHK from cationic region 2. 
SPARC was cleaved by proteases that are present in tissues 
and mediate matrix turnover, such as elastase and stromely- 
sin, and by the broad-spectrum serine proteases trypsin and 
subtilisin. Interestingly, SPARC was cleaved by thrombin, a 
potent activator of endothelial cells and platelets, to yield a 
stable intermediate that might subsequently be susceptible to 
other  enzymes.  Previous  studies  have  also  shown  that 
SPARC is digested by ,-chymotrypsin and pepsin (Sage et 
al., 1984), human leukocyte elastase (Maurer et al., 1992), 
and an uncharacterized metalloprotease secreted by osteo- 
blasts (Tyree, 1989).  The susceptibility of SPARC to pro- 
tease cleavage by leukocyte elastase and c~-chymotrypsin is 
dependent on the concentration of calcium ion (Maurer et 
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cated at amino acid 109 (Maurer et al., 1992),  amino acids 
near the GHK site appear to be exposed and susceptible to 
proteolysis. The sequence GHK occurs in a variety of pro- 
teins but is underrepresented in proteins that are secreted 
from mammalian cells. The pair of basic residues (KK) that 
flanks the GHK site makes the context of  the GHK sequence, 
as a conserved motif, unique to vertebrate SPARC proteins 
and provides a target for a variety of enzymes. Such sites are 
frequently cleaved by serine proteases and by members of  the 
subtilisin family of endoproteinases. Our analysis of GHK 
sequences in other proteins indicates that they could have 
arisen by chance, since these sites are not generally con- 
served across species. 
The involvement of copper and copper complexes in an- 
giogenesis has received considerable interest. Copper has 
been shown to accumulate in tissues before vascularization 
(Ziche et al.,  1982;  Apelgot et al.,  1986) and systemically 
during  an  inflammatory  response  (reviewed  in  Linder, 
1991). Copper-deficient animals have a diminished response 
to angiogenic stimulation (Ziche et al., 1982) and fail to vas- 
cularize implantedtumors effectively (Brem et al.,  1990). 
The concentration of available copper complexes directly 
affects the  synthesis  of fibronectin  and  collagen by  en- 
dothelial cells (Hannan and McAuslan,  1982),  as well as 
their migration in vitro (Alessandri et al., 1983).  These ob- 
servations have led to the hypothesis that copper ion is re- 
quired for one or several steps in blood vessel formation. 
Previous studies with several copper-containing complexes, 
including Cu:GHK, have shown an extensive stimulation of 
new vessel growth in vivo, whereas apoGHK had little effect 
(Raju et al., 1982).  Studies by the same group showed that 
Cu:GHK affected endothelial migration minimally in vitro 
(Alessandri et al., 1983). In the present studies, both KGHK 
and GHK stimulated cord formation in vitro; however, GHK 
required previous treatment with copper salts to acquire ac- 
tivity. We have shown that KGHK is a potent stimulator of 
angiogenesis, both in the CAM in vivo and in an assay of en- 
dothelial cord stimulation in vitro.  Although KGHK was 
shown to bind Cu  2+, the peptide did not appear to require 
previous loading with Cu  2÷ to manifest angiogenic activity. 
At the present time, we are unable to distinguish the effect 
of KGHK from that of the Cu:KGHK complex. Amino acid 
substitutions that eliminated Cu  2+ binding also diminished 
angiogenesis. Thus, there is a formal possibility that copper 
ion contributed by the cells is required for KGHK activity, 
a hypothesis that we could not test because our cells have an 
absolute growth requirement for trace levels of copper. 
The production of SPARC by endothelial cells of develop- 
ing capillaries, as well as by platelets and other connective 
tissue cells, provides a source of the protein that correlates 
temporally and spatially with the formation of neovascular 
sprouts during development and tissue repair. We propose 
that  SPARC  contributes  to  the  formation of new  vessel 
growth initially through its effects on endothelial cell shape 
and protein synthesis (Sage et al., 1989b; Lane et al., 1992). 
Subsequently, the protein is cleaved into bioactive peptides, 
one or more of which stimulate the morphogenesis of cords. 
We propose  the  following sequence  for the  activities of 
SPARC:  (a)  tissues undergoing remodeling and vascular 
growth produce high levels of SPARC; (b) SPARC is bound 
by the extracellular matrix or is released into a soluble com- 
partment; (c) SPARC interacts with cells to modulate adhe- 
sion, proliferation, and matrix deposition; (d) stimulation of 
endothelial cells, platelet degranulation, or recruitment of 
inflammatory cells results in the release of specific proteases 
that degrade SPARC;  and (e) cleavage products of SPARC 
manifest new functions and access new compartments not 
available to the intact protein. Cleavage of SPARC by plas- 
min provides an intriguing pathway, since this proteinase is 
closely regulated during angiogenesis (Rifkin et al.,  1982; 
Pepper and Montesano, 1990; Bacharach et al., 1992).  The 
activation of plasmin itself has been shown to be controlled 
by various angiogenic growth factors (Montesano and Orci, 
1985;  Montesano et al.,  1986),  and SPARC is a feedback 
regulator of  this process through its increase of  PAI-1 expres- 
sion in angiogenic endothelial cells (Hasselaar et al., 1991; 
Lane et al.,  1992). 
From our data, it appears that SPARC could be cleaved by 
several proteases present in extracellular fluids. Although 
SPARC has traditionally been viewed as a regulator of cell- 
matrix interactions and matrix synthesis (Sage and Born- 
stein, 1991; Sage et al., 1992), the intact protein could also 
be viewed as a source of bioactive peptides associated with 
a  larger  domain.  Long  regulatory  sequences  have  been 
identified as masking domains (latency structures) or as tar- 
geting signals in peptide hormones, growth factors, and en- 
zymes (Neurath,  1989;  Roberts and Sporn,  1992).  Studies 
that have demonstrated the association of SPARC with de- 
veloping or remodeling extracellular matrices could be rein- 
terpreted in the context of a precursor protein that releases 
active peptides through specific proteolysis. Thus, SPARC 
might be a regulator of  the distribution and activity  of  KGHK 
or GHK. 
In view of the existing evidence for the selective expres- 
sion  of  SPARC  during  angiogenesis,  and  the  literature 
describing the expression of this gene during development 
and tissue remodeling, the fate of SPARC in extraceUular 
fluids is of considerable importance. We provide evidence 
that SPARC might regulate vascular growth, a function that 
is enhanced by the action of specific proteases. The sequence 
GHK in a highly conserved, protease-sensitive domain of 
SPARC provides a potential substrate for the action of these 
enzymes. Since the source of GHK in plasma (or serum) is 
not known, we propose that at least a portion of this circulat- 
ing peptide is derived from SPARC. 
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